VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

Michael A. Poch, MD
Published: Friday, Aug 26, 2016


Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

In bladder cancer, checkpoint inhibition has proven to be an exciting concept, Poch explains. Checkpoint inhibitors block the downregulation of the immune cell, whether it’s nivolumab or pembrolizumab (Keytruda) on the PD-1 side, or whether it’s atezolizumab (Tecentriq) or durvalumab on the PD-L1 side, he adds.

Thus far, encouraging responses have been observed in patients who have failed cisplatin-based chemotherapy. In June 2016, the FDA granted nivolumab a priority review designation as a potential treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen, primarily based on findings from the phase II CA209-275 trial.

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

In bladder cancer, checkpoint inhibition has proven to be an exciting concept, Poch explains. Checkpoint inhibitors block the downregulation of the immune cell, whether it’s nivolumab or pembrolizumab (Keytruda) on the PD-1 side, or whether it’s atezolizumab (Tecentriq) or durvalumab on the PD-L1 side, he adds.

Thus far, encouraging responses have been observed in patients who have failed cisplatin-based chemotherapy. In June 2016, the FDA granted nivolumab a priority review designation as a potential treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen, primarily based on findings from the phase II CA209-275 trial.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x